Array ( [slave_lp] => Array ( [hostname] => 129.80.64.116 [username] => lpe [password] => jhvnaRSw98*#Je [database] => local_pages [dbdriver] => mysqli [dbprefix] => [pconnect] => [db_debug] => [cache_on] => [cachedir] => [char_set] => utf8 [dbcollat] => utf8_general_ci [swap_pre] => [autoinit] => 1 [stricton] => ) ) Array ( [slave_lp] => Array ( [hostname] => 129.80.64.116 [username] => lpe [password] => jhvnaRSw98*#Je [database] => local_pages [dbdriver] => mysqli [dbprefix] => [pconnect] => [db_debug] => [cache_on] => [cachedir] => [char_set] => utf8 [dbcollat] => utf8_general_ci [swap_pre] => [autoinit] => 1 [stricton] => ) ) Array ( [slave_lp] => Array ( [hostname] => 129.80.64.116 [username] => lpe [password] => jhvnaRSw98*#Je [database] => local_pages [dbdriver] => mysqli [dbprefix] => [pconnect] => [db_debug] => [cache_on] => [cachedir] => [char_set] => utf8 [dbcollat] => utf8_general_ci [swap_pre] => [autoinit] => 1 [stricton] => ) ) Array ( [slave_lp] => Array ( [hostname] => 129.80.64.116 [username] => lpe [password] => jhvnaRSw98*#Je [database] => local_pages [dbdriver] => mysqli [dbprefix] => [pconnect] => [db_debug] => [cache_on] => [cachedir] => [char_set] => utf8 [dbcollat] => utf8_general_ci [swap_pre] => [autoinit] => 1 [stricton] => ) )

Alvotech clinical study results demonstrate therapeutic equivalence between biosimilar candidate avt06 and reference product eylea® (aflibercept)

Alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced positive top-line results from a confirmatory clinical study for avt06, alvotech's proposed biosimilar to eylea® (aflibercept).
ALVO Ratings Summary
ALVO Quant Ranking